Ophthotech reported a net loss of $13.1 million, or $0.36 per diluted share, for the first quarter of 2018 compared with a net loss of $43.1 million, or $1.20 per diluted share, for the same time period of 2017.
Research and development costs decreased from $32 million in the first 3 months of 2017 to $7.7 million in 2018, according to a press release. The decrease was partially attributed to the discontinuation of the Fovista phase 3 clinical program.
General and administrative costs were $5.6 million for the quarter compared (Read more...)
Uncategorized